HER2+ 유방암 | 바이오정보모아

AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4

효능 ORR 76.7%임상시험 90상태 ACTIVE

AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody)

Breast Neoplasms · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+3

효능 ORR 20%임상시험 3상태 ACTIVE

ADCBiologicstaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

ADCBiologicstaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 RECRUITING

CGTBiologicstaleImugene LimitedPhase 1

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

ADCBiologicstaleXijing HospitalPhase 2

RC48-ADC (Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent, Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC))

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 ACTIVE